The United Kingdom and the United States have hammered out a major bilateral deal that will guarantee no levies on UK pharmaceutical exports entering the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to increase spending on drugs through the public health system. This move ensures that import taxes on these key goods will remain at zero for a timeframe of 36 months.
This deal is in response to previous warnings to dramatically increase duties on branded pharmaceutical products, with increases floated reaching double the cost.
"This agreement with the UK reinforces the international landscape for innovative medicines and brings much-needed fairness to American-British pharmaceutical trade," a statement noted.
Economic Importance
Drugs constitute one of the UK's most significant export categories to the US, which is clearly the biggest destination for leading British pharmaceutical firms.
Export figures reveal that in the year to the end of September, the UK shipped drugs valued at over eleven billion pounds to the US. This figure accounted for 17.4% of all goods exports in that span.
"This agreement safeguards employment, boosts investment and sets the stage for the UK to emerge as a international leader for biotech and pharma," a government official commented.
Specific UK Commitments
The pact involves several key changes from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to increase overall NHS spending on drugs from 0.3% of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The sum pharmaceutical firms must return to the NHS to control costs will be limited at 15%. Last year, refunds topped 20%.
Broader Context
This agreement comes amid a long-running row between the sector and the British authorities over medicine costs and approval rates.
These tensions were intensified by assertions that US patients were paying a premium for the equivalent treatments than patients in the other developed nations.
Recently, several major drug company projects in the UK have been paused or abandoned, while substantial funding commitments have been directed toward American operations.
One official stated that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
